Madrigal's Rezdiffra Secures First MASH Treatment Approval in Europe via EMA
EU Grants First MASH New Drug Status and Regulatory Approval
Madrigal Pharmaceuticals' Rezdiffra (resmetirom) has officially obtained Conditional Marketing Authorization from the European Commission (EC), following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA). This approval is granted for adult patients with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) accompanied by moderate to severe liver fibrosis (stages F2–F3), to be used in conjunction with diet and exercise. Following its FDA accelerated approval in March 2024, Rezdiffra has established itself as the first and only targeted MASH therapy authorized across all 27 EU member states. This represents a monumental milestone for the biopharmaceutical industry, setting a regulatory standard in the field of liver disease treatment, where unmet medical needs have been immense.
Liver Fibrosis Improvement Proven by Large-Scale Phase 3 MAESTRO-NASH Trial
This approval by European regulatory authorities is firmly rooted in the robust 52-week biopsy data from the pivotal Phase 3 'MAESTRO-NASH' study published in the New England Journal of Medicine (NEJM). Rezdiffra, a once-daily oral thyroid hormone receptor-beta (THR-β) agonist, demonstrated overwhelming statistical superiority over the placebo group (9.7%), achieving MASH resolution without worsening fibrosis at rates of 25.9% in the 80mg dose group and 29.9% in the 100mg dose group. Simultaneously, it demonstrated significant therapeutic benefits compared to the placebo group in the rate of improvement of at least one stage of liver fibrosis without worsening of the NAFLD Activity Score (NAS). It successfully met strict European regulatory guidelines by demonstrating excellent tolerability, with no fatal side effects observed other than initial mild diarrhea and nausea.
Establishing Global Blockbuster Status and First-Mover Advantage in a $40 billion Market
The global MASH treatment market is projected to experience explosive growth, reaching an annual scale of $20 billion to up to $40 billion (USD) by the mid-2030s, driven by the expansion of diagnostic infrastructure and the increasing population with obesity and diabetes. Since commencing US commercialization in 2024, Rezdiffra has already settled on a successful blockbuster trajectory, approaching an annual revenue run rate of approximately $1 billion within one year. This European authorization provides a decisive foothold to secure patient populations in major Western European countries (EU4 and the UK, etc.), which constitute the world’s second-largest pharmaceutical market following the United States. Based on its independent commercialization infrastructure, Madrigal is expected to further widen the gap with latecomers by establishing early control over local major gastroenterology society networks and distribution channels.
Outlook on Competition with GLP-1 Class and Leadership in Combination Therapy Market
The MASH treatment market is set for intense competition as pipelines from major diabetes and obesity treatments, such as Novo Nordisk's Wegovy (semaglutide, GLP-1 receptor agonist, Phase 3 ESSENCE) and Eli Lilly's Zepbound (tirzepatide, GIP/GLP-1 dual agonist), enter the fray. Additionally, FGF21 analog candidates such as Akero Therapeutics' efruxifermin and 89bio's pegozafermin are advancing toward Phase 3 trials. However, Rezdiffra, which has a mechanism of direct action on hepatocytes, has high potential to become an indispensable backbone therapy as a complementary combination partner to GLP-1 class drugs that work through metabolic weight loss mechanisms. The rich Real-World Data (RWD) and safety profile accumulated as a first mover will serve as a solid moat amidst the intensifying market competition in the future.
The European conditional marketing authorization obtained by Madrigal Pharmaceuticals (MDGL) for Rezdiffra is a decisive turning point for expanding its first-mover advantage across Western Europe in the global MASH market, which is expected to expand to $40 billion by the mid-2030s. The clinical evidence of at least 1-stage improvement in liver fibrosis and MASH resolution rates of up to 29.9% demonstrated in the Phase 3 MAESTRO-NASH trial will serve as the core clinical basis for driving drug price negotiations and early reimbursement listings in various European countries. As the entry of large-scale competing GLP-1 class drugs, such as Novo Nordisk's semaglutide (Phase 3 ESSENCE) and Eli Lilly's tirzepatide, into the MASH market becomes visible, [drug name] has secured a structural advantage to position itself not only as a leader in the monotherapy market but also as an essential backbone for future combination therapies as a direct-targeting oral agent. In the short term, drug pricing and the establishment of sales distribution networks in major countries such as Germany and France will be key catalysts for corporate value; in the medium to long term, it will fundamentally enhance the company's fundamentals through the generation of exclusive annual cash flows amounting to several billion dollars across the US and Europe.
Source: EMA (ema)